Search All UT System Experts

Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer

Amanda Kirane, Jason E. Toombs, Katherine Ostapoff, Juliet G. Carbon, Sara Zaknoen, Jordan Braunfeld, Roderich E. Schwarz, Francis J. Burrows, Rolf A. Brekken

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences